OpenAI 称 GPT-Rosalind 发现神经退行性疾病新药物线索
GPT-Rosalind surfaced a new lead for drug discovery: could restoring cholesterol transport protect neurons from degeneration?
OpenAI 表示 GPT-Rosalind 在药物发现中提出新线索：与 Perry 综合征相关的 DCTN1 基因被破坏后，小鼠脑数据中胆固醇合成相关基因表达上升，模型据此推测胆固醇可能未到达神经元所需位置。OpenAI 与 Perturb Bio、Scripps Research 合作，数千个 GPT-Rosalind 智能体并行工作，在 32 分钟内将数百万小鼠脑细胞的基因表达结果与科学文献关联起来。OpenAI 称正扩大这一合作以寻找新的药物靶点。
推荐理由
AI 评分 58
原文给出一个具体科研发现和 32 分钟完成跨百万细胞与文献关联的流程，可看多智能体并行在药物靶点发现中的用法。
主题
正文
当前显示原文，中文全文译文尚未就绪。
GPT-Rosalind surfaced a new lead for drug discovery: could restoring cholesterol transport protect neurons from degeneration?
DCTN1 is a gene linked to Perry syndrome, a rare neurodegenerative disorder. In mouse-brain data, disrupting it increased expression of genes involved in making cholesterol. GPT-Rosalind suggested a possible explanation: cholesterol may not be reaching where neurons need it.
That gives scientists a specific mechanism to test and, if confirmed, a direction for developing new treatments for neurodegenerative disorders.
With @perturbai_tx and @scrippsresearch, a team of thousands of GPT-Rosalind agents worked in parallel, connecting gene-expression results from millions of mouse brain cells with scientific literature in just 32 minutes. We’re now expanding this collaboration to identify new drug targets.